Stocktoria
Amneal Pharmaceuticals, Inc. AMRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-11-18
Amneal Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B |
| Gross profit | $1.1B | $1.0B | $820.6M | $784.7M | $769.0M |
| R&D expense | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M |
| SG&A expense | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M | $152.7M |
| Income tax | $11.3M | $18.9M | $8.5M | $6.7M | $11.2M |
| Net income | $72.1M | -$116.9M | -$84.0M | -$270.6M | $13.2M |
| EPS (diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M |
| Free cash flow | $269.9M | $243.2M | $302.4M | $18.7M | $194.1M |
| Cash & equivalents | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M |
| Total assets | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B |
| Shareholders' equity | -$71.3M | -$109.5M | $20.0M | $298.4M | $367.0M |
Source: SEC EDGAR filings · CIK 0001723128 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.